Онкогематология (Jul 2014)
Detection of 11q23 (MLL) rearrangements in infant acute lymphoblastic leukemia
- G. A. Tsaur,
- A. M. Popov,
- O. V. Aleynikova,
- E. G. Boychenko,
- T. Yu. Verzhbitskaya,
- E. V. Volochnik,
- A. S. Ivanova,
- O. V. Kalennik,
- S. Yu. Kovalev,
- K. L. Kondtratchik,
- A. M. Kustanovich,
- E. S. Lapotentova,
- D. V. Litvinov,
- I. S. Martynkevich,
- N. V. Myakova,
- T. V. Nasedkina,
- V. A. Ovsepyan,
- Yu. V. Olshanskaya,
- O. M. Plehanova,
- A. V. Popa,
- T. O. Riger,
- L. I. Savelyev,
- O. V. Streneva,
- M. V. Strigaleva,
- I. V. Shmunk,
- E. V. Shorikov,
- L. G. Fechina
Affiliations
- G. A. Tsaur
- Regional Children’s Hospital № 1 Research Institute of Medical Cell Technologies
- A. M. Popov
- Regional Children’s Hospital № 1 Research Institute of Medical Cell Technologies
- O. V. Aleynikova
- Belarusian Research Center for Pediatric Oncology and Hematology
- E. G. Boychenko
- Children’s Municipal Hospital № 1
- T. Yu. Verzhbitskaya
- Regional Children’s Hospital № 1 Research Institute of Medical Cell Technologies
- E. V. Volochnik
- Belarusian Research Center for Pediatric Oncology and Hematology
- A. S. Ivanova
- Regional Children’s Hospital № 1 Research Institute of Medical Cell Technologies
- O. V. Kalennik
- Engelgardt Institute of Molecular Biology Russian Academy of Science
- S. Yu. Kovalev
- B. Eltsyn Ural Federal University
- K. L. Kondtratchik
- Morozov Pediatric Municipal Clinical Hospital
- A. M. Kustanovich
- Belarusian Research Center for Pediatric Oncology and Hematology
- E. S. Lapotentova
- Belarusian Research Center for Pediatric Oncology and Hematology
- D. V. Litvinov
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
- I. S. Martynkevich
- Russian Research Institute of Hematology and Transfusiology
- N. V. Myakova
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
- T. V. Nasedkina
- Engelgardt Institute of Molecular Biology Russian Academy of Science
- V. A. Ovsepyan
- Kirov Research Institute of Hematology and Transfusiology
- Yu. V. Olshanskaya
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
- O. M. Plehanova
- Regional Children’s Hospital № 1
- A. V. Popa
- Ural State Medical Academy
- T. O. Riger
- Regional Children’s Hospital № 1 Research Institute of Medical Cell Technologies
- L. I. Savelyev
- Regional Children’s Hospital № 1 Research Institute of Medical Cell Technologies Ural State Medical Academy
- O. V. Streneva
- Regional Children’s Hospital № 1 Research Institute of Medical Cell Technologies
- M. V. Strigaleva
- Regional Children’s Hospital № 1
- I. V. Shmunk
- Chelyabinsk Regional Blood Transfusion Station
- E. V. Shorikov
- Regional Children’s Hospital № 1 Research Institute of Medical Cell Technologies
- L. G. Fechina
- Regional Children’s Hospital № 1 Research Institute of Medical Cell Technologies
- Journal volume & issue
-
Vol. 6,
no. 3
pp. 57 – 64
Abstract
117 cases of infant acute lymphoblastic leukemia without Down syndrome (aged from 1 to 365 days) were included in the current study.Rearrangements of 11q23 (MLL) were revealed in 74 (63.2 %) patients. Among this group the most common rearrangement was t(4;11) q21;q23)/MLL-AF4 detected in 63.5 % cases, less frequently was found t(11;19)(q23;p13)/MLL-MLLT1 (in 18.9 % cases), t(10;11) p12;q23)/MLL-MLLT10 and t(1;11)(p32;q23)/ML L-EPS15 (each one in 6.8 %), t(9;11)(p22;q23)/MLL-MLLT3 in 2.7 %. Children under 6 months of age had significantly higher incidence of 11q23 (ML L) rearrangements in comparison with infants olde r than 6 months (84.0 % vs. 47.8 %, p < 0.001). P atients with translocations 11q23 (ML L) more frequently had BI-A LL and less frequently BII-ALL than children without these rearrangements (p < 0.001 f or both). Fusion gene transcript w as sequenced in 26 ML Lrearranged cases. Depending on breakpoint position within ML L and partner genes we detected 7 differ ent types of ML L-AF4 fusion gene transcript, 3 types of MLL-MLLT1, 2 types of MLL-EPS15. The most common fusion site within MLL gene was exon 11, detected in 14 (53.8 %) patients.
